Cardiovascular Journal of Africa: Vol 32 No 2 (MARCH/APRIL 2021)

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 32, No 2, March/April 2021

AFRICA

107

Vesterlund T,

et al

. Long-term follow-up of patients from a randomised

trial of atrial versus ventricular pacing for sick-sinus syndrome.

Lancet

1997;

350

(9086): 1210–1216.

32. Kristensen L, Nielsen JC, Mortensen PT, Pedersen OL, Pedersen AK,

Andersen HR. Incidence of atrial fibrillation and thromboembolism in

a randomised trial of atrial versus dual chamber pacing in 177 patients

with sick sinus syndrome.

Heart

2004;

(6): 661–666.

33. Lamas GA, Orav EJ, Stambler BS, Ellenbogen KA, Sgarbossa EB,

Huang SK,

et al

. Quality of life and clinical outcomes in elderly patients

treated with ventricular pacing as compared with dual-chamber pacing.

N Engl J Med

1998;

338

(16): 1097–1104.

34. Nielsen JC, Kristensen L, Andersen HR, Mortensen PT, Pedersen OL,

Pedersen AK. A randomized comparison of atrial and dual-chamber pacing

in177 consecutive patients with sick sinus syndrome: Echocardiographic

and clinical outcome

. J Am Coll Cardiol

2003;

(4): 614–623.

35. Sweeney MO, Bank AJ, Nsah E, Koullick M, Zeng QC, Hettrick D,

. Minimizing ventricular pacing to reduce atrial fibrillation in sinus-

node disease.

N Engl J Med

2007;

357

(10): 1000–1008.

36. Garcia Talavera CS, Devesa Arbiol A, Benezet-Mazuecos J, Iglesias JA,

De La Vieja JJ, Serrano E,

et al

. Is ventricular pacing a new predictor for

atrial high rate episodes in patients with pacemakers?

Eur Heart J

2018;

(suppl 1): ehy566–6623.

37. Devesa Arbiol A, Garcia Talavera C, Benezet-Mazuecos J, Iglesias JA,

De La Vieja JJ, Serrano E,

et al

. Atrial pacing: A new predictor for atrial

high rate episodes in patients with dual-chamber pacemakers.

Eur Heart

2018;

(suppl 1): 564–620.

38. Tekkesin AI, Çinier G, Cakilli Y, Hayıro

lu M

, Alper AT. Interatrial

block predicts atrial high rate episodes detected by cardiac implantable

electronic devices.

J Electrocardiol

2017;

(2): 234–237.

39. Rubio Campal JM, Benezet‐Mazuecos J, Iglesias Bravo JA, Sánchez

Borque P, Miracle Blanco Á, de la Vieja Alarcón JJ,

et al

. P‐wave and

interatrial block: New predictor for atrial high rate episodes in patients

with cardiac implantable electronic devices.

Pacing Clin Electrophysiol

2018;

(3): 223–228.

40. Lamm G, Auer J, Weber T, Berent R, Ng C, Eber B. Postoperative

white blood cell count predicts atrial fibrillation after cardiac surgery.

Cardiothorac Vasc Anesth

2006;

(1): 51–56.

41. Friedrichs K, Klinke A, Baldus S. Inflammatory pathways underlying

atrial fibrillation.

Trends Molec Med

2011;

(10): 556–563.

42. Guo Y, Lip GY, Apostolakis S. Inflammation in atrial fibrillation.

J Am

Coll Cardiol

2012;

(22): 2263–2270.

43. Grosu AI, Radulescu D, Grosu LC, Pop D. Remodelling in atrial fibril-

lation: the impact of amiodarone.

Cardiovasc J Afr

2019;

(3): 174–180.

44. Pastori D, Miyazawa K, Li Y, Shahid F, Hado H, Lip GY. Inflammation

and the risk of atrial high-rate episodes (AHREs) in patients with

cardiac implantable electronic devices.

Clin Res Cardiol

2018;

107

(9):

772–777.

45. Bunch TJ, May HT. Atrial fibrillation: a risk factor or risk marker?

Eur

Heart J

2016;

(38): 2890–2892.

46. Affirm Investigators. Baseline characteristics of patients with atrial

fibrillation: the AFFIRM Study.

Am Heart J

2002;

143

(6): 991–1001.

47. Lip GY, Beevers DG. ABC of atrial fibrillation: history, epidemiology,

and importance of atrial fibrillation.

Br Med J

1995;

311

(7016): 1361.

48. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natu-

ral history of atrial fibrillation: incidence, risk factors, and prognosis in

the Manitoba Follow-Up Study.

Am J Med

1995;

(5): 476–484.

49. Healey JS, Connolly SJ, Gold MR, Israel CW, Van Gelder IC, Capucci

et al

. Subclinical atrial fibrillation and the risk of stroke.

N Engl J

Med

2012;

366

(2): 120–129.

50. Miyazawa K, Pastori D, Li YG, Székely O, Shahid F, Boriani G,

. Atrial high rate episodes in patients with cardiac implantable elec-

tronic devices: implications for clinical outcomes.

Clin Res Cardiol

2019;

108

(9): 1034–1041.

51. Pastori D, Miyazawa K, Li Y, Székely O, Shahid F, Farcomeni A,

. Atrial high-rate episodes and risk of major adverse cardiovascular

events in patients with cardiac implantable electronic devices.

Clin Res

Cardiol

2020;

109

(1): 96–102.

52. Van Gelder IC, Healey JS, Crijns HJ, Wang J, Hohnloser SH, Gold

MR,

et al

. Duration of device-detected subclinical atrial fibrillation and

occurrence of stroke in ASSERT.

Eur Heart J

2017;

(17): 1339–1344.

53. Boriani G, Glotzer TV, Santini M, West TM, De Melis M, Sepsi M,

. Device-detected atrial fibrillation and risk for stroke: an analysis of >

10 000 patients from the SOS AF project (Stroke preventiOn Strategies

based on Atrial Fibrillation information from implanted devices).

Eur

Heart J

2014;

(8): 508–516.

54. Wolf P, Kannel WB, McGee DL, Meeks SL, Bharucha NE, McNamara

PM. Duration of atrial fibrillation and imminence of stroke: the

Framingham study

. Stroke

1983;

(5): 664–667.

55. Sherman DG, Kim SG, Boop BS, Corley SD, DiMarco JP, Hart RG,

et al

. Occurrence and characteristics of stroke events in the Atrial

Fibrillation Follow-up Investigation of Sinus Rhythm Management

(AFFIRM) study.

Arch Int Med

2005;

165

(10): 1185–1191.

56. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland

JC,

et al

. 2019 AHA/ACC/HRS focused update of the 2014 AHA/

ACC/HRS guideline for the management of patients with atrial fibrilla-

tion: a report of the American College of Cardiology/American Heart

Association Task Force on Clinical Practice Guidelines and the Heart

Rhythm Society.

J Am Coll Cardiol

2019;

(1): 104–132.

57. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B,

et al

2016 ESC guidelines for the management of atrial fibrillation developed

in collaboration with EACTS.

Eur J Cardio-Thorac Surg

2016;

(5):

e1–88.

58. Kaplan RM, Koehler J, Ziegler PD, Sarkar S, Zweibel S, Passman RS.

Stroke risk as a function of atrial fibrillation duration and CHA

VASc score.

Circulation

2019;

140

(20): 1639–1646.

59. Capucci A, Santini M, Padeletti L, Gulizia M, Botto G, Boriani G,

. Monitored atrial fibrillation duration predicts arterial embolic events

in patients suffering from bradycardia and atrial fibrillation implanted

with antitachycardia pacemakers.

J Am Coll Cardiol

2005;

(10):

1913–1920.

60. Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Zolezzi F,

. Presence and duration of atrial fibrillation detected by continuous

monitoring: crucial implications for the risk of thromboembolic events.

J Cardiovasc Electrophysiol

2009;

(3): 241–248.

61. Shanmugam N, Boerdlein A, Proff J, Ong P, Valencia O, Maier SK,

. Detection of atrial high-rate events by continuous home monitor-

ing: clinical significance in the heart failure – cardiac resynchronization

therapy population

. Europace

2012;

(2): 230–237.

62. Crijns HJ, van Gelder IC, van Gilst WH, Hillege H, Gosselink AM, Lie

KI. Serial antiarrhythmic drug treatment to maintain sinus rhythm after

electrical cardioversion for chronic atrial fibrillation or atrial flutter.

J Cardiol

1991;

(4): 335–341.